SPHERA FUNDS MANAGEMENT LTD.

13F Filings History

Latest 13F report
Q4 2024 - Feb 14, 2025
Value $
$541M
Signature - Title
Oshrat Levi - Chief Financial Officer
Location
Tel Aviv, Israel
Summary
This page shows a list of all the recent 13F filings made by SPHERA FUNDS MANAGEMENT LTD.. Form 13F is required to be filed within 45 days of the end of a calendar quarter. SPHERA FUNDS MANAGEMENT LTD. reported 103 stock holdings with total value $541M as of Q4 2024. Top holdings included TEVA, BBIO, SNY, SNDX, and AZN.
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Date Filed
Q4 2024 103 $541M +$102M -$125M -$23M TEVA, BBIO, SNY, SNDX, AZN 13F-HR 2/14/2025, 02:33 PM
Q3 2024 108 $610M +$137M -$136M +$886K TEVA, SNY, BBIO, SNDX, AMZN 13F-HR 11/14/2024, 03:15 PM
Q2 2024 110 $610M +$168M -$126M +$42.6M BBIO, SNY, CYTK, AMZN, SNDX 13F-HR 8/14/2024, 03:36 PM
Q1 2024 91 $615M +$179M -$175M +$4.35M TEVA, SNY, NICE, CYTK, SNDX 13F-HR 5/15/2024, 03:42 PM
Q4 2023 88 $533M +$155M -$214M -$58.3M TEVA, SNY, CYTK, NVMI, SNDX Restatement 2/15/2024, 07:40 AM
Q3 2023 106 $549M +$159M -$227M -$68.1M TEVA, SNY, AZN, NICE, JNJ 13F-HR 11/14/2023, 03:54 PM
Q2 2023 108 $640M +$259M -$237M +$21.6M TEVA, QQQ, SNY, AZN, JNJ 13F-HR 8/14/2023, 04:45 PM
Q1 2023 81 $598M +$377M -$33.5M +$344M IWM, SPY, SNY, NICE, AZN 13F-HR 5/15/2023, 04:14 PM
Q4 2022 63 $466M +$123M -$287M -$164M AZN, SNY, JNJ, SNDX, MRK 13F-HR 2/14/2023, 02:36 PM
Q3 2022 71 $712M +$356M -$76.1M +$280M AZN, LLY, SNY, JNJ, MRK 13F-HR 11/14/2022, 03:20 PM
Q2 2022 54 $926M +$530M -$38.9M +$491M QQQ, SPY, AZN, JNJ, LLY 13F-HR 8/15/2022, 03:32 PM
Q1 2022 66 $703M +$235M -$135M +$99.9M AZN, JNJ, SNY, QQQ, ABBV 13F-HR 5/16/2022, 03:34 PM
Q4 2021 89 $879M +$255M -$214M +$41.5M ABBV, AZN, SNY, LLY, MRK 13F-HR 2/14/2022, 02:24 PM
Q3 2021 107 $1.01B +$351M -$350M +$235K LLY, AZN, ABBV, PFE, SNY 13F-HR 11/15/2021, 03:41 PM
Q2 2021 120 $1.05B +$259M -$356M -$97.1M AZN, JNJ, MRK, SNY, GNRC 13F-HR 8/16/2021, 06:15 PM
Q1 2021 158 $1.09B +$463M -$305M +$158M LLY, JNJ, ABBV, MRK, SNY 13F-HR 5/17/2021, 06:01 AM
Q4 2020 109 $1.13B +$499M -$232M +$267M LLY, SRPT, MRK, JNJ, XBI 13F-HR 2/16/2021, 05:29 AM
Q3 2020 91 $993M +$346M -$108M +$238M MRK, ABBV, QQQ, JNJ, SNY 13F-HR 11/12/2020, 05:59 AM
Q2 2020 87 $1.06B +$453M -$101M +$352M XBI, ABBV, MRK, SPY, SNY 13F-HR 8/13/2020, 06:02 AM
Q1 2020 77 $795M +$353M -$265M +$87.9M IWM, MRK, SPY, JNJ, BMY 13F-HR 5/14/2020, 07:49 AM
Q4 2019 86 $1.21B +$678M -$126M +$552M XBI, IBB, JNJ, BMY, SNY 13F-HR 2/13/2020, 11:11 AM
Q3 2019 79 $647M +$242M -$54.4M +$188M BMY, JNJ, GILD, MRK, SNY 13F-HR 11/14/2019, 05:01 AM
Q2 2019 89 $731M +$235M -$42.9M +$192M JNJ, ALXN, BMY, MRK, AZN 13F-HR 8/14/2019, 06:02 AM
Q1 2019 0 New Holdings 6/20/2019, 07:37 AM
Q1 2019 102 $1.09B +$373M -$136M +$237M XBI, BMY, JNJ, FOLD, ALXN 13F-HR 5/15/2019, 06:23 AM
Q4 2018 88 $747M +$301M -$83.3M +$217M XBI, MYL, MRK, BMY, CELG 13F-HR 2/14/2019, 05:42 AM
Q3 2018 111 $869M +$397M -$45.3M +$351M XBI, MRK, MYL, JNJ, GSKXXXX 13F-HR 11/14/2018, 11:39 AM
Q2 2018 106 $715M +$326M -$103M +$224M MRK, MYL, GSKXXXX, GILD, SHPG 13F-HR 8/13/2018, 08:30 AM
Q1 2018 104 $646M +$195M -$168M +$27.3M XBI, MRK, SHPG, CELG, FOLD 13F-HR 5/10/2018, 08:44 AM
Q4 2017 132 $846M +$305M -$66.1M +$239M XBI, IBB, CELG, MYL, MRK 13F-HR 2/12/2018, 01:44 PM
Q3 2017 128 $694M +$288M -$34.9M +$253M XBI, CELG, BIIB, MRK, GILD Restatement 11/27/2017, 09:57 AM
Q2 2017 126 $577M +$209M -$89.1M +$120M CELG, BIIB, MRK, GSKXXXX, GILD 13F-HR 8/9/2017, 10:08 AM
Q1 2017 108 $490M +$197M -$5.98B -$5.78B CELG, BIIB, NVS, MRK, SRPT 13F-HR 5/11/2017, 06:08 AM
Q4 2016 103 $391M +$115M -$111M +$4.01M MRK, CELG, TEVA, ALXN, CLCD 13F-HR 2/13/2017, 07:44 AM
Q3 2016 106 $612M +$316M -$92.6M +$223M MRK, TEVA, SRPT, AGN, LLY 13F-HR 11/14/2016, 06:46 AM
Q2 2016 89 $357M +$149M -$99.5M +$49.7M TEVA, AGN, GILD, LLY, CELG 13F-HR 8/10/2016, 10:17 AM
Q1 2016 88 $445M +$182M -$33.9M +$148M PFE, TEVA, BIIB, AGN, GILD 13F-HR 5/16/2016, 06:17 AM
Q4 2015 116 $639M +$266M -$107M +$159M TEVA, PFE, BIIB, AGN, ABBV 13F-HR 2/11/2016, 08:46 AM
Q3 2015 122 $713M +$311M -$96.5M +$215M AGN, TEVA, BIIB, PFE, ABBV 13F-HR 11/16/2015, 05:05 AM
Q2 2015 122 $981M +$387M -$89.3M +$297M AGN, GILD, PFE, ABBV, BIIB 13F-HR 8/6/2015, 01:19 PM
Q1 2015 142 $932M +$557M -$3.12B -$2.56B B108PS, PFE, GILD, TEVA, ABBV 13F-HR 5/11/2015, 06:43 AM
Q4 2014 119 $548M +$184M -$123M +$61.4M NVS, B108PS, PFE, TEVA, SLXP 13F-HR 2/12/2015, 11:42 AM
Q3 2014 122 $751M +$462M -$51.8M +$410M NVS, PFE, TEVA, B108PS, MRK Restatement 11/20/2014, 06:33 AM
Q2 2014 96 $379M +$148M -$70.1M +$78.2M NVS, MRK, TEVA, JNJ, PFE Restatement 8/20/2014, 06:03 AM
Q1 2014 105 $395M +$199M -$135M +$64.2M NVS, GSKXXXX, MRK, PFE, JNJ 13F-HR 5/14/2014, 12:02 PM
Q4 2013 95 $357M GSKXXXX, PFE, XLF, MRK, SHPG 13F-HR 2/13/2014, 01:03 PM